Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Amarantus Bioscience Holdings, Inc. (AMBS) Starts Presentation at the 4th Annual LD Micro Conference

Posted on June 4, 2014 by MissionIR

Amarantus BioScience Holdings, Inc. (OTC: AMBS) is a development-stage biotechnology company focusing on the discovery and development of drug candidates and diagnostic blood tests to diagnose and treat human diseases. The company is developing the Mesencephalic-Astrocyte-derived Neurotrophic Factor, a therapeutic protein for treating Parkinson’s disease; LymPro, a blood test to diagnose Alzheimer’s disease; NuroPro to diagnose neurodegenerative diseases; and BC-SeraPro to diagnose breast cancer. For more information, visit the company’s website at www.amarantus.com

The three-day LD Micro Invitational in Bel Air, California, features company presentations from more than 200 select high-potential small-cap companies spanning multiple industries. Institutional and retail investors in attendance also have access to numerous networking opportunities and social events to learn more about these companies. For more information on LD Micro, visit www.ldmicro.com
This entry was posted in LD Micro Conference. Bookmark the permalink.

Comments are closed.